News | September 17, 2007

DuraHeart Hits a 77 Percent Survival Rate

September 18, 2007 - The DuraHeart Left Ventricular Assist System (LVAS) reported a survival rate of 77 percent for all patients at 1 and 2 years, according to Aly El-Banayosy, M.D., from the Heart Center Nordrhein-Westfalen in Bad Oeynhausen, Germany, who presented a summary of the results from the European Clinical Trial at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland.

The clinical results from the 33 patient study on the DuraHeart device, manufactured by Terumo Heart Inc., which had a median age of 57 years of age (29-73), included:
* mean support duration (days) = 231±194 (range: 17-803)
* cumulative support duration = 7610 days (> 20 years)
* 7 patients (21%) supported > 1 year, and one supported > 2 years.
* 12 patients (36%) remain on support with a mean duration > 1 year (375± 196 days)
* Kaplan Meier survival at 1 and 2 years was: 77% (all patients), 80% (

The DuraHeart LVAS is a third generation circulatory support device intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is currently the only approved implantable LVAS combining a centrifugal pump with magnetic levitation of the impeller, reportedly minimizing the potential for blood damage and thrombus. DuraHeart is not available in the United States.

For more information: www.terumo.com

Related Content

FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Overlay Init